Biopharmx Corp (NYSEAMERICAN:BPMX) dropped 7.7% during trading on Monday . The stock traded as low as $0.11 and last traded at $0.12. Approximately 3,014,200 shares traded hands during mid-day trading, an increase of 103% from the average daily volume of 1,487,068 shares. The stock had previously closed at $0.13.

BPMX has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Biopharmx in a research note on Wednesday, September 13th. Maxim Group decreased their price objective on shares of Biopharmx from $3.00 to $1.50 and set a “buy” rating for the company in a research note on Wednesday, September 13th.

Biopharmx (NYSEAMERICAN:BPMX) last released its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). Biopharmx had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.

In related news, Director Stephen Morlock acquired 330,000 shares of the company’s stock in a transaction dated Friday, November 24th. The stock was bought at an average cost of $0.15 per share, with a total value of $49,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The disclosure for this sale can be found here.

ILLEGAL ACTIVITY WARNING: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2017/12/06/biopharmx-bpmx-trading-down-7-7.html.

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.